Description

The CardioMetabolic Profile evaluates a broad range of biomarkers that assess cardiovascular disease (CVD) risk and metabolic dysfunction linked to metabolic syndrome and type 2 diabetes. This panel provides deep insight into lipid metabolism, inflammation, insulin resistance, kidney function, and vascular health, enabling early detection of risk factors and guiding personalized prevention and treatment strategies.

Biomarkers Included and Their Significance

  • 1,5-Anhydroglucitol (1,5-AG):
  • Reflects short-term glucose control; low levels indicate recent hyperglycemia episodes missed by HbA1c.
  • Adiponectin:
  • A protective adipokine that improves insulin sensitivity and has anti-inflammatory effects. Low levels are linked to metabolic syndrome and CVD risk.
  • Apolipoprotein A1 (Apo A1):
  • Main protein component of HDL (“good cholesterol”); higher levels are protective.
  • Apolipoprotein B (Apo B):
  • Represents the total number of atherogenic particles, including LDL; elevated levels increase cardiovascular risk.
  • Apo B/Apo A1 Ratio:
  • A strong predictor of cardiovascular risk, balancing harmful vs. protective lipoproteins.
  • Creatinine:
  • Kidney function marker; elevated levels may indicate impaired renal clearance, impacting cardiovascular health.
  • Cystatin C:
  • Another sensitive kidney function marker useful for early detection of kidney disease.
  • Fasting Glucose:
  • Assesses baseline blood sugar; elevated levels signal impaired glucose metabolism or diabetes risk.
  • Fasting Insulin:
  • Indicates insulin resistance; high insulin levels suggest metabolic dysfunction.
  • High-Density Lipoprotein (HDL):
  • “Good cholesterol” involved in reverse cholesterol transport; higher levels are protective.
  • Homocysteine:
  • Elevated levels are associated with endothelial dysfunction and increased cardiovascular risk.
  • Low-Density Lipoprotein (LDL):
  • “Bad cholesterol” that contributes to plaque formation in arteries.
  • LDL/HDL Ratio:
  • Helps assess cardiovascular risk by comparing harmful vs. protective cholesterol.
  • Leptin:
  • Hormone regulating appetite and metabolism; elevated levels can indicate leptin resistance linked to obesity and metabolic syndrome.
  • Leptin/Adiponectin Ratio:
  • Reflects balance between pro-inflammatory and anti-inflammatory adipokines; higher ratio indicates increased cardiometabolic risk.
  • Lipoprotein(a) [Lp(a)]:
  • A genetically determined lipid particle linked to increased atherosclerosis risk.
  • Lipoprotein-Associated Phospholipase A2 (Lp-PLA2):
  • Marker of vascular inflammation and plaque instability.
  • Total Cholesterol (TC):
  • Overall cholesterol level in blood.
  • Triglycerides:
  • Elevated levels indicate impaired lipid metabolism and increased CVD risk.
  • Very-Low-Density Lipoprotein (VLDL):
  • Carries triglycerides; elevated levels contribute to atherogenesis.
  • Estimated Glomerular Filtration Rate (eGFR):
  • Assesses kidney filtration capacity; decreased eGFR indicates kidney impairment.
  • High-Sensitivity C-Reactive Protein (hs-CRP):
  • Sensitive marker of systemic inflammation linked to cardiovascular risk.
  • Non-HDL Cholesterol:
  • Total cholesterol minus HDL; represents all atherogenic lipoproteins.
  • Oxidized LDL (ox-LDL):
  • Modified LDL that promotes inflammation and plaque formation; a strong atherogenic factor.
  • OxLDL/LDL Ratio:
  • Indicates the proportion of LDL that is oxidized, providing insight into oxidative stress burden.
  • Small Dense LDL (sdLDL):
  • A more atherogenic subtype of LDL particles; higher levels increase cardiovascular risk.
  • sdLDL/LDL Ratio:
  • Proportion of small dense LDL relative to total LDL, important for refined risk assessment.

Why This Panel Matters

Cardiovascular disease remains a leading cause of mortality worldwide, often preceded by metabolic dysfunction that can go unnoticed for years. This panel’s comprehensive markers allow:

  • Early detection of metabolic syndrome and diabetes risk
  • Detailed evaluation of lipid quality, not just quantity
  • Insight into vascular inflammation and oxidative stress
  • Assessment of kidney function’s impact on cardiometabolic health
  • Identification of hormone imbalances (leptin/adiponectin) driving metabolic dysfunction
  • Personalized interventions targeting root causes such as insulin resistance, inflammation, oxidative damage, and kidney health

Who Should Consider This Panel

  • Individuals with family history of cardiovascular disease or diabetes
  • Patients with obesity, hypertension, or metabolic syndrome
  • Those experiencing elevated cholesterol or blood sugar despite lifestyle changes
  • People seeking advanced risk assessment beyond traditional lipid panels
  • Anyone wanting proactive cardiovascular and metabolic health optimization